Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
127,672,444
-
Total 13F shares
-
105,373,378
-
Share change
-
-4,803,546
-
Total reported value
-
$9,599,421,028
-
Put/Call ratio
-
74%
-
Price per share
-
$91.10
-
Number of holders
-
308
-
Value change
-
-$395,834,493
-
Number of buys
-
162
-
Number of sells
-
148
Institutional Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q2 2023
As of 30 Jun 2023 Apellis Pharmaceuticals, Inc. - Common Stock (APLS) had 308 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 105,373,378 shares of stock of the company.
Largest 10 holders included Avoro Capital Advisors LLC, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., T. Rowe Price Investment Management, Inc., EcoR1 Capital, LLC, FMR LLC, Octagon Capital Advisors LP, and STATE STREET CORP.
This table shows 311 institutional shareholders of the security as of 30 Jun 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.